As per the recently published report by MarketsandMarket™, The global liquid biopsy market is projected to grow from USD 4.03 billion in 2025 to USD 7.05 billion by 2030, at a CAGR of 11.8% during the forecast period. Market growth is primarily driven by the increasing global incidence of cancer and the growing demand for non-invasive, efficient, and patient-friendly diagnostic solutions.
Browse 482 market data Tables and 60 Figures spread through 392 Pages and in-depth TOC on “Liquid Biopsy Market – Global Forecast to 2030”.
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=13966350
Advancements in next-generation sequencing (NGS) and digital PCR technologies have significantly enhanced the sensitivity and specificity of liquid biopsy assays, enabling accurate detection of genetic mutations and real-time monitoring of disease progression. Additionally, increasing awareness initiatives and national cancer screening programs are supporting early diagnosis, further accelerating market adoption.
NGS-Based Multi-Gene Analysis Leads Technology Segment
By technology, multi-gene parallel analysis using NGS accounted for the largest share of the market in 2024. This segment’s dominance is attributed to its ability to analyze multiple genetic alterations simultaneously, providing comprehensive molecular profiling with high accuracy.
NGS-based approaches offer high-throughput capabilities and flexibility, making them well-suited for clinical applications such as therapy selection, treatment monitoring, and detection of complex genomic variations. The growing integration of NGS into personalized medicine and routine diagnostics is further driving segment growth.
Cancer Applications Drive Market Demand
By application, the cancer segment accounted for the largest share of the liquid biopsy market in 2024. The rising global burden of cancer and increasing research in oncology are major factors contributing to this dominance.
Liquid biopsy enables non-invasive detection and monitoring of tumors, including real-time assessment of tumor progression and identification of minimal residual disease. It also addresses limitations associated with traditional tissue biopsies, such as invasiveness and sampling constraints, making it an increasingly preferred diagnostic approach in oncology.
Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=13966350
North America Leads Global Market
North America held the largest share of the liquid biopsy market in 2024. The region’s leadership is supported by well-established healthcare infrastructure, advanced diagnostic capabilities, and a strong network of specialized cancer care centers.
The presence of skilled healthcare professionals and early adoption of innovative technologies further contribute to widespread implementation of liquid biopsy solutions. Additionally, supportive regulatory frameworks and increasing investments in precision medicine are driving continued market growth in the region.
Competitive Landscape
Key players operating in the liquid biopsy market include Natera, Inc. (US), QIAGEN (Netherlands), Guardant Health (US), Illumina, Inc. (US), F. Hoffmann-La Roche Ltd. (Switzerland), Thermo Fisher Scientific Inc. (US), GRAIL, Inc. (US), Bio-Rad Laboratories, Inc. (US), Exact Sciences Corporation (US), and Sysmex Corporation (Japan).
These companies are focusing on technological innovation, strategic collaborations, and expansion of product portfolios to strengthen their position in the rapidly evolving liquid biopsy landscape.
Related Reports:
Biopsy Devices Market – Global Forecast to 2030
Biomarkers Market – Global Forecast to 2031
Media ContactCompany Name: MarketsandMarkets™ Research Private Ltd.Contact Person: Mr. Rohan SalgarkarEmail: Send EmailPhone: 18886006441Address:1615 South Congress Ave. Suite 103, Delray Beach, FL 33445City: FloridaState: FloridaCountry: United StatesWebsite: https://www.marketsandmarkets.com/Market-Reports/liquid-biopsy-market-13966350.html
